migraine
Fellowship of Pain, Episode 1: Stellate Ganglion Block for Refractory Migraine
Eric Jones, MD, discusses a case involving use of a stellate ganglion block for refractory migraine in the debut ...
FEBRUARY 14, 2025
New Research Shows Atogepant Works Quickly to Prevent Migraines
New research suggests that atogepant, a calcitonin gene−related peptide receptor antagonist, may work ...
JANUARY 10, 2025
Medicating Migraine in Prodrome Can Avert Headache, Facilitate Functioning
Ubrogepant taken in the prodrome phase of migraine was superior to placebo in staving off an acute episode, and in ...
DECEMBER 26, 2024
New Research Links Higher Diastolic Blood Pressure With Migraines
A new study has found that women with higher diastolic blood pressure are more likely to have migraines, indicating ...
AUGUST 5, 2024
AHS Announces Headache and Migraine Competitive Grant Program
The American Headache Society is partnering with Pfizer to launch the Headache and Migraine Competitive Grant ...
JUNE 6, 2024
Feelings of Stigma Associated With Migraine
People with migraine experience stigma associated with more disability, increased disease burden and reduced ...
JANUARY 19, 2024
Study Shows Atogepant Prevents Migraine In Difficult Cases
A recent study has shown that atogepant (Qulipta, AbbVie), may help prevent migraines in people who have had no ...
AUGUST 25, 2023
Review Assesses Utility of Psychological Interventions for Migraine
There has not been a consensus statement on treating migraine from a U.S. or an international headache consortium ...
JUNE 7, 2023
FDA Approves Atogepant to Prevent Chronic Migraine in Adults
Atogepant becomes the first oral CRGP receptor antagonist approved to prevent both episodic and chronic ...
APRIL 19, 2023
Targeting Number of Monthly Headache Days for Chronic Migraine Management
For people who have chronic migraine, four monthly migraine days may be an ideal treatment target, according to ...
APRIL 6, 2023
Test Predicts Response to Key Migraine Therapy With 86% Accuracy
A quick, inexpensive and noninvasive proprietary test is an 86% accurate pretreatment predictor of anti-calcitonin ...
MARCH 14, 2023
FDA Approves CGRP Nasal Spray for Acute Migraine Treatment
The FDA approved zavegepant (Zavzpret, Pfizer) as the first calcitonin gene–related peptide (CGRP) receptor ...
MARCH 14, 2023
